keyword
MENU ▼
Read by QxMD icon Read
search

Oncotype

keyword
https://www.readbyqxmd.com/read/29920746/pathologist-s-health-care-value-in-the-triage-of-oncotype-dx-%C3%A2-testing-a-value-based-pathology-study-of-tumor-biology-with-outcomes
#1
David J Dabbs, Beth Z Clark, Kate Serdy, Agnieszka Onisko, Adam Brufsky, Sherie Smalley, Stephen Perkins, Rohit Bhargava
BACKGROUND: Pathologists provide expert tissue assessment of breast cancer, yet their value to guide the appropriate use of breast cancer gene expression profile (GEP) tests is underutilized. The specific aims of this study are to report morpho-immunohistologic characteristics of breast tumors with Oncotype DX® (ODx) Recurrence Scores (RS) of 10 or less (ultra-low risk) and 25 or less (low risk) in order to determine if pathologists can prospectively identify patient tumors that do not require ODx testing...
June 19, 2018: Histopathology
https://www.readbyqxmd.com/read/29848291/quantitative-nuclear-histomorphometry-predicts-oncotype-dx-risk-categories-for-early-stage-er-breast-cancer
#2
Jon Whitney, German Corredor, Andrew Janowczyk, Shridar Ganesan, Scott Doyle, John Tomaszewski, Michael Feldman, Hannah Gilmore, Anant Madabhushi
BACKGROUND: Gene-expression companion diagnostic tests, such as the Oncotype DX test, assess the risk of early stage Estrogen receptor (ER) positive (+) breast cancers, and guide clinicians in the decision of whether or not to use chemotherapy. However, these tests are typically expensive, time consuming, and tissue-destructive. METHODS: In this paper, we evaluate the ability of computer-extracted nuclear morphology features from routine hematoxylin and eosin (H&E) stained images of 178 early stage ER+ breast cancer patients to predict corresponding risk categories derived using the Oncotype DX test...
May 30, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29796180/gene-expression-profiling-in-prognosis-of-distant-recurrence-in-hr-positive-and-her2-negative-breast-cancer-patients
#3
Tzu-Ting Huang, Nicolas Pennarun, Yu-Hao Cheng, Cheng-Fang Horng, Jason Lei, Skye Hung-Chun Cheng
There had been several studies using gene-expression profiling in predicting distant recurrence in breast cancer. In this study, we developed an 18-gene classifier (18-GC) to predict distant recurrence of breast cancer and compared it with the 21-gene panel (Oncotype DX® , ODx) in performance. Included were 224 breast cancer patients with positive hormonal receptor (HR+) and negative human epidermal growth factor receptor 2 (HER2-). We compared the demographic, clinical, and survival information of the patients, and further compared the prediction of recurrence risk obtained by using the 18-GC with that by ODx...
May 1, 2018: Oncotarget
https://www.readbyqxmd.com/read/29788166/combined-pathologic-genomic-algorithm-for-early-stage-breast-cancer-improves-cost-effective-use-of-the-21-gene-recurrence-score-assay
#4
M M Gage, W C Mylander, M Rosman, T Fujii, F Le Du, A Raghavendra, A K Sinha, J R Espinosa Fernandez, A James, N T Ueno, L Tafra, R S Jackson
Background: The 21-gene recurrence score (RS) (Oncotype DX®; Genomic Health, Redwood City, CA) partitions hormone receptor positive, node negative breast cancers into three risk groups for recurrence. The Anne Arundel Medical Center (AAMC) model has previously been shown to accurately predict RS risk categories using standard pathology data. A pathologic-genomic (P-G) algorithm then is presented using the AAMC model and reserving the RS assay only for AAMC intermediate-risk patients...
May 1, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29737473/uptake-of-brca-1-2-and-oncotype-dx-testing-by-medical-and-surgical-oncologists
#5
Yonina R Murciano-Goroff, Anne Marie McCarthy, Mirar N Bristol, Peter Groeneveld, Susan M Domchek, U Nkiru Motanya, Katrina Armstrong
PURPOSE: The diffusion of genomic testing is critical to the success of precision medicine, but there is limited information on oncologists' uptake of genetic technology. We aimed to assess the frequency with which medical oncologists and surgeons order BRCA 1/2 and Oncotype DX testing for breast cancer patients. METHODS: We surveyed 732 oncologists and surgeons treating breast cancer patients. Physicians were from Florida, New York, New Jersey, and Pennsylvania, and were listed in the 2010 AMA Masterfile or identified by patients...
May 8, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29718314/simulation-modeling-of-cancer-clinical-trials-application-to-omitting-radiotherapy-in-low-risk-breast-cancer
#6
Jinani Jayasekera, Yisheng Li, Clyde B Schechter, Reshma Jagsi, Juhee Song, Julia White, George Luta, Judith-Anne W Chapman, Eric J Feuer, Richard C Zellars, Natasha Stout, Thomas B Julian, Timothy Whelan, Xuelin Huang, E Shelley Hwang, Judith O Hopkins, Joseph A Sparano, Stewart J Anderson, Anthony W Fyles, Robert Gray, Willi Sauerbrei, Jeanne Mandelblatt, Donald A Berry
Background: We used two models to simulate a proposed noninferiority trial of radiotherapy (RT) omission in low-risk invasive breast cancer to illustrate how modeling could be used to predict the trial's outcomes, inform trial design, and contribute to practice debates. Methods: The proposed trial was a prospective randomized trial of no-RT vs RT in women age 40 to 74 years undergoing lumpectomy and endocrine therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative, stage I breast cancer with an Oncotype DX score of 18 or lower...
April 28, 2018: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/29691722/applying-new-magee-equations-for-predicting-the-oncotype-dx-recurrence-score
#7
Maher Sughayer, Rolla Alaaraj, Ahmad Alsughayer
BACKGROUND: Breast cancer is one of the most prevalent cancers in women. Oncotype Dx is a multi-gene assay frequently used to predict the recurrence risk for estrogen receptor-positive early breast cancer, with values < 18 considered low risk; ≥ 18 and ≤ 30, intermediate risk; and > 30, high risk. Patients at a high risk for recurrence are more likely to benefit from chemotherapy treatment. METHODS: In this study, clinicopathological parameters for 37 cases of early breast cancer with available Oncotype Dx results were used to estimate the recurrence score using the three new Magee equations...
April 24, 2018: Breast Cancer: the Journal of the Japanese Breast Cancer Society
https://www.readbyqxmd.com/read/29679201/utilization-of-the-21-gene-recurrence-score-in-a-diverse-breast-cancer-patient-population-development-of-a-clinicopathologic-model-to-predict-high-risk-scores-and-response-to-neoadjuvant-chemotherapy
#8
Ko Un Park, Yalei Chen, Dhananjay Chitale, Sarah Choi, Haythem Ali, S David Nathanson, Jessica Bensenhaver, Erica Proctor, Lindsay Petersen, Randa Loutfi, Alyson Simonds, Marcia Kuklinski, Thomas Doyle, Vrushali Dabak, Kim Cole, Melissa Davis, Lisa Newman
INTRODUCTION: The 21-gene expression profile [Oncotype DX Recurrence Score (RS)] stratifies benefit from adjuvant chemotherapy in hormone receptor (HR)-positive, HER2/neu-negative, node-negative breast cancer. It is not routinely applied to predict neoadjuvant chemotherapy (NACT) response; data in diverse patient populations also are limited. We developed a statistical model based on standard clinicopathologic features to identify high-risk cases (RS > 30) and then evaluated ability of predicted high RS to predict for NACT downstaging...
July 2018: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/29659329/cost-effectiveness-analyses-of-the-21-gene-assay-in-breast-cancer-systematic-review-and-critical-appraisal
#9
Shi-Yi Wang, Weixiong Dang, Ilana Richman, Sarah S Mougalian, Suzanne B Evans, Cary P Gross
Purpose Prior studies examining cost effectiveness of the 21-gene assay (Oncotype DX [ODX]) for women with hormone receptor-positive, early-stage breast cancer have yielded disparate results. We aimed to explore why these analyses may have yielded different conclusions. Methods We conducted a systematic literature review of cost-effectiveness analyses (CEAs) of ODX. We examined the extent to which the structure of CEA modeling, the assumptions of the models, and the selection of input parameters influenced cost-effectiveness estimates...
June 1, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29602380/-consensus-statement-on-biomarkers-in-breast-cancer-by-the-spanish-society-of-pathology-and-the-spanish-society-of-medical-oncology
#10
José Palacios Calvo, Joan Albanell, Federico Rojo, Eva Ciruelos, Ignacio Aranda-López, Javier Cortés, Tomás García-Caballero, Miguel Martín, María Ángeles López-García, Ramon Colomer
This consensus statement is a joint initiative of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM). It revises and updates the recommendations for the use of biomarkers in the diagnosis and treatment of breast cancer. The group of experts recommends that, in all cases of breast cancer, the histologic grade and the alpha-estrogen receptor (ER), progesterone receptor, Ki-67 and HER2 status should be determined, in order to assist prognosis and establish therapeutic options, including hormone therapy, chemotherapy and anti-HER2 therapy...
April 2018: Revista Española de Patología
https://www.readbyqxmd.com/read/29524506/a-17-gene-genomic-prostate-score-assay-provides-independent-information-on-adverse-pathology-in-the-setting-of-combined-mpmri-fusion-targeted-and-systematic-prostate-biopsy
#11
Amirali Salmasi, Jonathan Said, Alan W Shindel, Pooria Khoshnoodi, Ely R Felker, Anthony E Sisk, Tristan Grogan, Debbie McCullough, John Bennett, Helen Bailey, H Jeffrey Lawrence, David A Elashoff, Leonard S Marks, Steven S Raman, Phillip G Febbo, Robert E Reiter
PURPOSE: Multiparametric MRI (mpMRI) and biopsy-based molecular tests such as the 17-gene Oncotype DX® Genomic Prostate Score™ (GPS) assay are increasingly used to improve risk stratification in men with clinically localized prostate cancer (PCa). The GPS assay was previously shown to be a significant independent predictor of adverse pathology (AP) at radical prostatectomy (RP) in men diagnosed with systematic biopsies only. We therefore investigated the ability of GPS to predict AP in the setting of MRI-guided prostate biopsy...
March 7, 2018: Journal of Urology
https://www.readbyqxmd.com/read/29503586/spotlight-on-the-utility-of-the-oncotype-dx-%C3%A2-breast-cancer-assay
#12
REVIEW
Zhen Rong Siow, Richard H De Boer, Geoffrey J Lindeman, G Bruce Mann
The Oncotype DX® assay was developed to address the need for optimizing the selection of adjuvant systemic therapy for patients with estrogen receptor (ER)-positive, lymph node-negative breast cancer. It has ushered in the era of genomic-based personalized cancer care for ER-positive primary breast cancer and is now widely utilized in various parts of the world. Together with several other genomic assays, Oncotype DX has been incorporated into clinical practice guidelines on biomarker use to guide treatment decisions...
2018: International Journal of Women's Health
https://www.readbyqxmd.com/read/29498449/her2-equivocal-breast-cancer-that-is-positive-by-alternative-probe-her2-fish-are-classified-as-her2-negative-by-oncotype-dx
#13
Gary H Tozbikian, Debra L Zynger
In breast cancer, human epidermal growth factor receptor 2 (HER2) status is determined by immunohistochemistry (IHC) and/or in situ hybridization. Oncotype DX also reports HER2 status by an rt-PCR-based assay. Assay concordance between IHC and fluorescent in situ hybridization (FISH) (including alternative probe HER2 FISH) vs Oncotype DX HER2 rt-PCR has not been described in the post-2013 American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) HER2 Guideline revision setting. We performed a retrospective review of HER2 equivocal invasive breast carcinoma from 2014 to 2016 with the Oncotype DX HER2 result...
March 2, 2018: Breast Journal
https://www.readbyqxmd.com/read/29450494/comparison-of-the-performance-of-6-prognostic-signatures-for-estrogen-receptor-positive-breast-cancer-a-secondary-analysis-of-a-randomized-clinical-trial
#14
Ivana Sestak, Richard Buus, Jack Cuzick, Peter Dubsky, Ralf Kronenwett, Carsten Denkert, Sean Ferree, Dennis Sgroi, Catherine Schnabel, Frederick L Baehner, Elizabeth Mallon, Mitch Dowsett
Importance: Multiple molecular signatures are available for managing estrogen receptor (ER)-positive breast cancer but with little direct comparative information to guide the patient's choice. Objective: To conduct a within-patient comparison of the prognostic value of 6 multigene signatures in women with early ER-positive breast cancer who received endocrine therapy for 5 years. Design, Setting, and Participants: This retrospective biomarker analysis included 774 postmenopausal women with ER-positive ERBB2 (formerly HER2)-negative breast cancer...
April 1, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/29439886/patient-experiences-and-clinician-views-on-the-role-of-radiation-therapy-for-ductal-carcinoma-in-situ
#15
Dean A Shumway, Chandler M McLeod, Monica Morrow, Yun Li, Allison W Kurian, Aaron Sabolch, Ann S Hamilton, Kevin C Ward, Steven J Katz, Sarah T Hawley, Reshma Jagsi
PURPOSE: To evaluate patient experiences with decisions regarding radiation therapy (RT) for ductal carcinoma in situ (DCIS), and to assess clinician views on the role of RT for DCIS with favorable features in the present era. METHODS AND MATERIALS: A sample of women with newly diagnosed breast cancer from the population-based Georgia and Los Angeles County Surveillance, Epidemiology, and End Results (SEER) registries were sent surveys approximately 2 months after undergoing breast-conserving surgery (BCS), with a 70% response rate...
April 1, 2018: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/29427210/a-study-of-association-of-oncotype-dx-recurrence-score-with-dce-mri-characteristics-using-multivariate-machine-learning-models
#16
Ashirbani Saha, Michael R Harowicz, Weiyao Wang, Maciej A Mazurowski
PURPOSE: To determine whether multivariate machine learning models of algorithmically assessed magnetic resonance imaging (MRI) features from breast cancer patients are associated with Oncotype DX (ODX) test recurrence scores. METHODS: A set of 261 female patients with invasive breast cancer, pre-operative dynamic contrast enhanced magnetic resonance (DCE-MR) images and available ODX score at our institution was identified. A computer algorithm extracted a comprehensive set of 529 features from the DCE-MR images of these patients...
May 2018: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/29371476/prospective-evaluation-of-the-impact-of-the-21-gene-recurrence-score-assay-on-adjuvant-treatment-decisions-for-women-with-node-positive-breast-cancer-in-ontario-canada
#17
Sofia Torres, Maureen Trudeau, Sonal Gandhi, Ellen Warner, Sunil Verma, Kathleen I Pritchard, Teresa Petrella, Mark Hew-Shue, Calvin Chao, Andrea Eisen
BACKGROUND: The 21-gene Recurrence Score (RS) assay is only reimbursed in Ontario for node-negative and micrometastatic node-positive (N+) early-stage breast cancer (EBC). We carried out a prospective study to evaluate the impact of the assay on treatment decisions for women with N+ EBC. Subjects, Materials, and Methods . Women with estrogen receptor-positive, human epidermal growth receptor 2-negative EBC and one to three positive axillary lymph nodes, who were candidates for adjuvant chemotherapy in addition to hormonal treatment, but in whom the benefit of chemotherapy was uncertain, were eligible...
January 25, 2018: Oncologist
https://www.readbyqxmd.com/read/29366844/multigene-signature-panels-and-breast-cancer-therapy-patterns-of-use-and-impact-on-clinical-decision-making
#18
Neal Bhutiani, Michael E Egger, Nicolás Ajkay, Charles R Scoggins, Robert Cg Martin, Kelly M McMasters
BACKGROUND: A growing body of evidence supports the use of multigene signature panels (MSPs) in predicting recurrence risk in patients with invasive breast cancer. This study aimed to evaluate trends in MSP use over time and the effect of MSPs on administration of postoperative chemotherapy. STUDY DESIGN: The National Cancer Database was queried for all women with invasive breast cancer who underwent resection between 2011 and 2014 and had information about performance of an MSP, hormone receptor status, and receipt of chemotherapy...
April 2018: Journal of the American College of Surgeons
https://www.readbyqxmd.com/read/29349758/is-dcis-overrated
#19
Joshua Feinberg, Rachel Wetstone, Dana Greenstein, Patrick Borgen
Ductal carcinoma in situ (DCIS), the noninvasive form of breast cancer (BC), comprises just over 20% of breast cancer cases diagnosed each year in the USA. Most patients are treated with local excision of the disease followed by whole breast radiation therapy. Total mastectomy is not an uncommon approach, and total mastectomy with a contralateral risk-reducing mastectomy has been on the rise in the past decade. In estrogen receptor-positive disease, patients are often offered endocrine ablative therapy with a selective estrogen receptor modulator or an aromatase inhibitor as both treatment and prevention...
2018: Cancer Treatment and Research
https://www.readbyqxmd.com/read/29337486/improving-risk-stratification-among-veterans-diagnosed-with-prostate-cancer-impact-of-the-17-gene-prostate-score-assay
#20
Julie A Lynch, Megan P Rothney, Raoul R Salup, Cesar E Ercole, Sharad C Mathur, David A Duchene, Joseph W Basler, Javier Hernandez, Michael A Liss, Michael P Porter, Jonathan L Wright, Michael C Risk, Mark Garzotto, Olga Efimova, Laurie Barrett, Brygida Berse, Michael J Kemeter, Phillip G Febbo, Atreya Dash
BACKGROUND: Active surveillance (AS) has been widely implemented within Veterans Affairs' medical centers (VAMCs) as a standard of care for low-risk prostate cancer (PCa). Patient characteristics such as age, race, and Agent Orange (AO) exposure may influence advisability of AS in veterans. The 17-gene assay may improve risk stratification and management selection. OBJECTIVES: To compare management strategies for PCa at 6 VAMCs before and after introduction of the Oncotype DX Genomic Prostate Score (GPS) assay...
January 2018: American Journal of Managed Care
keyword
keyword
24782
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"